<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03603522</url>
  </required_header>
  <id_info>
    <org_study_id>McMaster- DSM17938-5095</org_study_id>
    <nct_id>NCT03603522</nct_id>
  </id_info>
  <brief_title>Probiotics and Capsaicin Evoked Coughs</brief_title>
  <acronym>PCEC</acronym>
  <official_title>A Double-Blind Randomized Placebo Controlled Trial Investigating the Effects of DSM17938 on Capsaicin Evoked Coughs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioGaia AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cough in asthma is a very common and troublesome symptom in asthma, which predicts severity&#xD;
      and poor prognosis. Previous studies have shown that asthmatics have an exaggerated cough&#xD;
      response to capsaicin. Currently available asthma treatment is not designed to target the&#xD;
      cough reflex directly, so this presents an unmet need for patients. The treatment being&#xD;
      tested in this study is the commercially available over the counter oral probiotic BioGaia®&#xD;
      DSM17938. Based on clinical and pre-clinical evidence, it is hypothesized that TRPV1&#xD;
      antagonism with BioGaia® DSM17938 will result in a reduction in capsaicin evoked coughs in&#xD;
      patients with asthma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Visit 1: Baseline Screening and Beginning of Treatment Period 1 Subjects will undergo&#xD;
      consent, complete history, physical examination, spirometry, capsaicin cough challenge, skin&#xD;
      prick testing (allergen and histamine), methacholine challenge, induced sputum and blood&#xD;
      sampling. Eligible subjects will then be randomized with matched oral BioGaia DSM17938 and&#xD;
      placebo and will be given for the next 4 weeks.&#xD;
&#xD;
      Visit 2: End of Treatment Period 1 Subjects will undergo spirometry, capsaicin cough&#xD;
      challenge, skin prick testing, methacholine challenge, sputum induction and blood testing.&#xD;
&#xD;
      Washout: 28 day washout period prior to Visit 3.&#xD;
&#xD;
      Visit 3: Beginning of Treatment Period 2 Subjects wills undergo all the same tests performed&#xD;
      in visit 2. Drug/Placebo will be given for the next 28 days.&#xD;
&#xD;
      Visit 4: End of Treatment Period 2 Subjects will undergo all the same tests performed in&#xD;
      visit 2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 16, 2019</start_date>
  <completion_date type="Actual">January 18, 2021</completion_date>
  <primary_completion_date type="Actual">January 18, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Participants will have a screening period followed by 28 days treatment with BioGaia DSM17938 or placebo, followed by a washout period and will then crossover to the opposite treatment received in the first part of the study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Emax</measure>
    <time_frame>Day 1, Day 30, Day 59 and Day 89</time_frame>
    <description>The maximum number of capsaicin evoked coughs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ED50 (median effective dose)</measure>
    <time_frame>Day 1, Day 30, Day 59 and Day 89</time_frame>
    <description>The dose of capsaicin that evokes at least half the maximum number of coughs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose response</measure>
    <time_frame>Day 1, Day 30, Day 59 and Day 89</time_frame>
    <description>Changes in the capsaicin full dose response curves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C2 and C5</measure>
    <time_frame>Day 1, Day 30, Day 59 and Day 89</time_frame>
    <description>Changes in the dose of capsaicin causing 2 coughs (C2) and 5 coughs (C5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responses to histamine</measure>
    <time_frame>Day 1, Day 30, Day 59 and Day 89</time_frame>
    <description>The wheal responses to graded doses of histamine skin prick testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Itch Intensity</measure>
    <time_frame>Day 1, Day 30, Day 59 and Day 89</time_frame>
    <description>The intensity of itch after skin prick testing using a modified Borg scale (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-Cell Cytokine</measure>
    <time_frame>Day 1, Day 30, Day 59 and Day 89</time_frame>
    <description>Inhibition of T-Cell cytokine responses to stimulation in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum differential cell counts</measure>
    <time_frame>Day 1, Day 30, Day 59 and Day 89</time_frame>
    <description>Changes in sputum differential cell counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PC20</measure>
    <time_frame>Day 1, Day 30. Day 59 and Day 89</time_frame>
    <description>Changes in methacholine PC20</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Atopic Asthma</condition>
  <arm_group>
    <arm_group_label>BioGaia-DSM17938 then Placebo Comparator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>28 days treatment with BioGaia-DSM17938, followed by 28 days washout and then crossover to 28 days placebo comparator treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator then BioGaia DSM17938</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>28 days treatment with placebo comparator treatment, followed by 28 days washout and then crossover to 28 days treatment with BioGaia DSM17938.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>BioGaia-DSM17938</intervention_name>
    <description>2mL per day (1x10^9 CFU) per day taken orally for 28 days</description>
    <arm_group_label>BioGaia-DSM17938 then Placebo Comparator</arm_group_label>
    <arm_group_label>Placebo Comparator then BioGaia DSM17938</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Comparator: Placebo Control</intervention_name>
    <description>2mL per day of placebo formulation taken orally for 28 days</description>
    <arm_group_label>BioGaia-DSM17938 then Placebo Comparator</arm_group_label>
    <arm_group_label>Placebo Comparator then BioGaia DSM17938</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged ≥18&#xD;
&#xD;
          2. Able to understand and give written informed consent&#xD;
&#xD;
          3. Has a diagnosis of atopic asthma (based on at least one positive skin prick test and&#xD;
             Methacholine PC20 ≤16 mg/ml)&#xD;
&#xD;
          4. FEV1 (forced expiratory volume at 1 second) ≥ 70% of predicted&#xD;
&#xD;
          5. Demonstrate a cough response to capsaicin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who are in a pollen season that affects their asthma&#xD;
&#xD;
          2. Subjects who bronchoconstrict by more than 10% at the end of the full dose capsaicin&#xD;
             cough challenge (assess after visit 1)&#xD;
&#xD;
          3. Subjects who do not display evidence of airway hyper-responsiveness (PC20&gt;16mg/ml)&#xD;
             (assess after visit 1)&#xD;
&#xD;
          4. Symptoms of upper respiratory tract infection (URTI) in the last 1 month which have&#xD;
             not resolved.&#xD;
&#xD;
          5. Lower respiratory tract infection or pneumonia in the last 6 weeks.&#xD;
&#xD;
          6. Current smoker or ex-smoker with ≥10 pack year smoking history and abstinence of ≤6&#xD;
             months&#xD;
&#xD;
          7. Asthma exacerbation in the previous month requiring an increase or start of an ICS&#xD;
             (inhaled corticosteroids) or OCS (oral corticosteroids)&#xD;
&#xD;
          8. Any asthma medication with the exception of infrequent (less than twice weekly)&#xD;
             short-acting beta-agonist.&#xD;
&#xD;
          9. Subjects who have changed asthma medication within the past 4 weeks prior to screening&#xD;
&#xD;
         10. A previous asthma exacerbation requiring Intensive Care Unit (ICU) admission.&#xD;
&#xD;
         11. Significant other primary pulmonary disorders in particularly; pulmonary embolism,&#xD;
             pulmonary hypertension, interstitial lung disease, lung cancer, cystic fibrosis,&#xD;
             emphysema or bronchiectasis.&#xD;
&#xD;
         12. Pregnancy or breast-feeding&#xD;
&#xD;
         13. Use of ACE (angiotensin converting enzyme) inhibitors&#xD;
&#xD;
         14. Any centrally acting medication which in the view of the investigator could alter the&#xD;
             sensitivity of the cough reflex&#xD;
&#xD;
         15. History of psychiatric illness, drug or alcohol abuse which may interfere in the&#xD;
             participation of the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail Gauvreau, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McMaster Cardio-Respiratory Research Lab</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>July 18, 2018</study_first_submitted>
  <study_first_submitted_qc>July 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cough</keyword>
  <keyword>Capsaicin</keyword>
  <keyword>Probiotics</keyword>
  <keyword>TRPV1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cough</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

